Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, a move that strengthens the company's expertise in biotechnology, drug delivery, and central nervous system clinical development. The additions come as Helus Pharma advances its pipeline of novel serotonergic agonists (NSAs), including programs targeting major depressive disorder and generalized anxiety disorder.
Dr. Robert Langer is a highly respected figure in biotechnology, known for his groundbreaking work in drug delivery systems. Dr. Stephen Brannan brings extensive experience in central nervous system clinical development. Their appointments are expected to support Helus Pharma's commitment to disciplined, evidence-based drug development aimed at addressing unmet needs in mental health. The company's lead program, HLP003, is a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder.
Helus Pharma, the commercial operating name of Cybin Inc., focuses on developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to provide durable improvements in mental health through its proprietary NSAs. With a robust research portfolio and operations in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is positioned to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. For more information, visit www.helus.com or follow the team on social media platforms.
This strategic addition to the Scientific Advisory Board underscores Helus Pharma's dedication to advancing its pipeline and leveraging top-tier scientific expertise to bring innovative treatments to market. The full press release is available at https://ibn.fm/CyjTq.
